HUYA Bioscience CEO Mireille Gillings: an “Outsider” Promoting Globalization of China’s Innovative Drugs
August 2016 – Harvard Business Review Chinese Edition
February 2016 – Bioworld Today
December 2015 – The Stevie Awards Blog
December 2015 – Bioworld Today
September 2014 – Bioworld Today
August 2014 – Bioworld Today
January 2013 – PharmAsia News
May 2009 – Scientific American
Turning traditional Chinese medicine modern and leading the way for new drugs
by Mara Hvistendahl
Wolfberry, licorice and caterpillar fungus. Such substances don’t sound like the makings of modern medicine, but they might soon be just that. China’s current five-year plan lists the “modernization” of traditional Chinese medicine (TCM) as one of 12 focal points, allotting 1 billion yuan ($146 million) for the task. The goal is to move away from philosophies like yin-yang and meridian theory and toward science-by introducing randomized, double-blind, placebo controlled trials…
February 6, 2009 – SCRIP World Pharmaceutical News
The pursuit of cost-effective innovation may have led many multinationals to build up their R&D activities in China recently, but one entrepreneur spotted the vast potential of the country’s research expertise several years ago. HUYA Bioscience International’s founder, president and CEO Dr Mireille Gingras, talks to Scrip’s Asia editor Ian Haydock…
January 8, 2009 – Xconomy.com
HUYA sources novel drug candidates to meet the growing needs of big pharma drug pipelines, interview with Mireille Gingras, CEO HUYA Bioscience
If there was an “ah-ha” moment for Huya Bioscience International, it occurred in 2004, when founder Mireille Gingras was working as a consultant for mid-size biotech companies…
November 13, 2008 – PharmaWeek
HUYA’s innovative Integrated Co-development Model for drug development is validated with Chinese-based Phase I clinical trial results on Chidamide (HBI-8000), a novel histone deacetylase (HDAC) inhibitor of the benzamide class.
October 2008 – Nature Reviews
Organizations worldwide have shown growing interest in China as a location for drug discovery and development. This month, we feature two people closely involved in harnessing the therapeutic potential of compounds discovered in China.
August 21, 2008 – PharmAsia News
July 21, 2008 – San Diego Business Journal
Risk reduction has always been an attractive business practice, but it has an especially sweet-sounding ring for drug firms looking to bring new medicines onto the market.